[go: up one dir, main page]

CL2015002239A1 - Modulators of methyl modifying enzymes, compositions comprising them and their uses - Google Patents

Modulators of methyl modifying enzymes, compositions comprising them and their uses

Info

Publication number
CL2015002239A1
CL2015002239A1 CL2015002239A CL2015002239A CL2015002239A1 CL 2015002239 A1 CL2015002239 A1 CL 2015002239A1 CL 2015002239 A CL2015002239 A CL 2015002239A CL 2015002239 A CL2015002239 A CL 2015002239A CL 2015002239 A1 CL2015002239 A1 CL 2015002239A1
Authority
CL
Chile
Prior art keywords
compositions
modulators
modifying enzymes
methyl modifying
methyl
Prior art date
Application number
CL2015002239A
Other languages
Spanish (es)
Inventor
Brian K Albrecht
James Edmund Audia
Andrew S Cook
Les A Dakin
Martin Duplessis
Victor S Gehling
Jean-Christophe Harmange
Christopher Nasveschuk
Rishi G Vaswani
Original Assignee
Constelllation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/025639 external-priority patent/WO2013120104A2/en
Application filed by Constelllation Pharmaceuticals Inc filed Critical Constelllation Pharmaceuticals Inc
Publication of CL2015002239A1 publication Critical patent/CL2015002239A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

AGENTES PARA MODULAR LAS ENZIMAS MODIFICADORAS DE LOS METILOS, COMPOSICIONES QUE LOS COMPRENDEN Y SUS USOS.AGENTS TO MODULATE THE MODIFIER ENZYMES OF THE METHODS, COMPOSITIONS THAT UNDERSTAND AND THEIR USES.

CL2015002239A 2013-02-11 2015-08-11 Modulators of methyl modifying enzymes, compositions comprising them and their uses CL2015002239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/025639 WO2013120104A2 (en) 2012-02-10 2013-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
CL2015002239A1 true CL2015002239A1 (en) 2016-02-05

Family

ID=50239937

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002239A CL2015002239A1 (en) 2013-02-11 2015-08-11 Modulators of methyl modifying enzymes, compositions comprising them and their uses

Country Status (16)

Country Link
EP (1) EP2953941B1 (en)
KR (1) KR102219441B1 (en)
CN (1) CN105102446B (en)
CL (1) CL2015002239A1 (en)
CR (1) CR20150457A (en)
IL (1) IL239985B (en)
MA (1) MA38341B1 (en)
ME (1) ME02730B (en)
PE (1) PE20160044A1 (en)
PH (1) PH12015501720B1 (en)
PL (1) PL2953941T3 (en)
RS (1) RS56207B1 (en)
SG (1) SG11201506077XA (en)
SI (1) SI2953941T1 (en)
TW (1) TWI629273B (en)
WO (1) WO2014124418A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US10220036B2 (en) 2014-12-23 2019-03-05 Novartis Ag Triazolopyrimidine compounds and uses thereof
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2017018975A1 (en) 2015-07-24 2017-02-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
HK1256604A1 (en) * 2015-08-03 2019-09-27 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (en) 2015-08-27 2017-06-01 美國禮來大藥廠 Inhibitors of EZH2
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
EP4309738A3 (en) 2015-10-06 2024-07-17 Epizyme, Inc. Method of treating medulloblastoma with an ezh2 inhibitor
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc Combination therapy for treating cancer
CN105669647B (en) * 2016-02-22 2018-05-04 上海皓元生物医药科技有限公司 A kind of synthetic method of histone methylase EZH2 inhibitor intermediates
MA45406A (en) 2016-06-17 2019-04-24 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
JP2019524872A (en) * 2016-06-20 2019-09-05 ノバルティス アーゲー Imidazopyrimidine compounds useful for the treatment of cancer
JP2019522049A (en) 2016-06-20 2019-08-08 ノバルティス アーゲー Triazolopyridine compounds and uses thereof
CA3027246A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
AU2017367768A1 (en) 2016-12-02 2019-07-18 Epizyme, Inc. Combination therapy for treating cancer
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018231973A1 (en) 2017-06-13 2018-12-20 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
WO2019014191A1 (en) 2017-07-10 2019-01-17 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
WO2019094552A1 (en) * 2017-11-09 2019-05-16 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
CN109879790B (en) * 2017-12-06 2022-09-20 华东师范大学 Amide micromolecule organic compound with indole or indole analogue as mother nucleus structure, application and preparation method thereof
WO2019133674A1 (en) 2017-12-28 2019-07-04 Constellation Pharmaceuticals, Inc. Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies
PT3746446T (en) 2018-01-31 2022-07-18 Mirati Therapeutics Inc PRC2 INHIBITORS
CN110229151B (en) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 Indolizine compound, preparation method and application thereof
CN110229157B (en) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 Pyrimido five-membered heteroaromatic compound, preparation method and application thereof
EP3765458B1 (en) 2018-03-14 2023-01-11 Biogen MA Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
AU2019344922B2 (en) 2018-09-19 2025-02-06 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
AR117252A1 (en) 2018-12-05 2021-07-21 Biogen Ma Inc MORPHOLINYL, PIPERAZINYL, OXAZEPANIL AND DIAZEPANIL O-GLUCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
WO2020139339A1 (en) 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
JP7504898B2 (en) 2019-02-04 2024-06-24 バイオジェン・エムエイ・インコーポレイテッド Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
US12421224B2 (en) 2019-03-08 2025-09-23 Biogen Ma Inc. Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
EP3959214A1 (en) 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
BR112022001161A2 (en) * 2019-07-24 2022-06-07 Constellation Pharmaceuticals Inc Crystalline forms of 7-Chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo- 1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxol-5-carboxamide
WO2021016409A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021086966A1 (en) 2019-10-29 2021-05-06 Biogen Ma Inc. Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
UY39366A (en) 2020-08-03 2022-02-25 Biogen Ma Inc CRYSTALLINE FORMS OF AN INHIBITOR OF O-GLUCOPROTEIN-2-ACETAMIDO-2-DESOXI-3-D-GLUCOPYRANOSIDASE
CN112679505B (en) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 Synthesis method of 4-methyl-7H-pyrrolo [2,3-d ] pyrimidine
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2566327T (en) * 2010-05-07 2017-05-26 Glaxosmithkline Llc INDOLES
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) * 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
EP2812001B1 (en) * 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
CN105102446A (en) 2015-11-25
TW201443038A (en) 2014-11-16
EP2953941A1 (en) 2015-12-16
ME02730B (en) 2017-10-20
MA38341B1 (en) 2018-11-30
PH12015501720A1 (en) 2015-11-09
HK1218648A1 (en) 2017-03-03
KR20150119201A (en) 2015-10-23
IL239985B (en) 2018-11-29
IL239985A0 (en) 2015-09-24
TWI629273B (en) 2018-07-11
EP2953941B1 (en) 2017-04-05
WO2014124418A1 (en) 2014-08-14
RS56207B1 (en) 2017-11-30
SG11201506077XA (en) 2015-08-28
CR20150457A (en) 2015-10-20
MA38341A1 (en) 2018-01-31
CN105102446B (en) 2018-01-23
KR102219441B1 (en) 2021-02-23
PE20160044A1 (en) 2016-02-11
PH12015501720B1 (en) 2015-11-09
PL2953941T3 (en) 2017-11-30
SI2953941T1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2015002239A1 (en) Modulators of methyl modifying enzymes, compositions comprising them and their uses
MX2022000053A (en) SESTRIN-GATOR2 INTERACTION MODULATORS AND THEIR USES.
CL2016000839A1 (en) Compositions to modulate the expression of c9orf72.
CR20150462A (en) ERK INHIBITORS AND THEIR USES
UY34484A (en) BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES
CL2017000576A1 (en) Mk2 inhibitors and their uses
PT2992009T (en) COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF APOLIPOPROTEIN (A)
MX387587B (en) SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND THEIR USES.
UY35485A (en) HETEROCYCLIC COMPOUNDS AND USES OF THE SAME
UY34636A (en) TOPICAL COMPOSITIONS THAT INCLUDE FIPRONYL AND PERMETRINE AND THEIR METHODS OF USE
MX385585B (en) ANTI-C10ORF54 ANTIBODIES AND THEIR USES.
TWD180147S (en) Water purifier
UY34876A (en) ANTI-EGFR ANTIBODIES AND USES OF THE SAME
UY35427A (en) COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN
ECSP14005975A (en) Anti-PHF-tau antibodies and their uses
CR20150549A (en) HETEROCYCLIC COMPOUNDS AND THEIR USES
UY33858A (en) MODULATORS OF THE COMPLEMENT PATH AND USES OF THE SAME
UY35425A (en) COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN
NI201400079A (en) NEW PIRROL DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
UY35426A (en) COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN
TWD179460S (en) locomotive
NI201400080A (en) NEW PHOSPHATE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
SV2017005395A (en) RORC2 PIRROLOPIRIDINE MODULATORS REPLACED WITH METHYL AND TRIFLUOROMETILE AND METHODS OF USE OF THE SAME
MX2015009479A (en) COMPOUNDS AND METHODS TO TREAT BACTERIAL INFECTIONS.
UY34773A (en) INDANOYLOXIDIHYDROBENZOFURANILACETIC ACIDS AS MODULATORS OF THE ACTIVITY OF GPR40, COMPOSITIONS CONTAINING THEM AND THEIR USES